PATENT CLAIM ANALYSIS

Application Number: 16100120
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "093210"]

Abstract:
The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCRαβ-deficient T cells and CD3/TCRαβ-deficient chimeric antigen receptor T cells that express such PEBLs.

Claim (Index 89):
The engineered CD3/TCR\u03b1\u03b2-deficient CAR-T cell of  claim 88 , wherein the scFv that binds CD3\u03b5 comprises a variable heavy chain (V H ) sequence having at least 95% sequence identity to SEQ ID NO:1 and a variable light chain (V L ) sequence having at least 95% sequence identity to SEQ ID NO:2.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15821170', '15965739', '15419398', '15094674', '13979927']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7822242394702082
- 35 USC 102 Novelty (BERT): 0.608937363838822
- Combined Prediction Score: 0.7648955519070696
- Mean Citation Score: 474.72279800000007
- Max Citation Score: 648.9918
- Similarity Product: 452.03265501229765

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test